Sanofi pulls the plug on ADC af­ter lung can­cer PhI­II dis­ap­points

The on­ly clin­i­cal-stage an­ti­body-drug con­ju­gate in Sanofi’s pipeline has flunked a Phase III study, push­ing the French drug­mak­er to wind down the en­tire de­vel­op­ment pro­gram …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER